Please login to the form below

Not currently logged in
Email:
Password:

nintedanib

This page shows the latest nintedanib news and features for those working in and with pharma, biotech and healthcare.

FDA clears wider use for Boehringer’s Ofev in lung disease

FDA clears wider use for Boehringer’s Ofev in lung disease

The regulator has approved Ofev (nintedanib) for treating chronic fibrosing ILDs with a progressive phenotype, and Boehringer’s drug is the first to be registered in the US for patients with

Latest news

More from news
Approximately 9 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    The drug is predicted to take a 50% share of the estimated $2bn IPF market, the main competitor being Boehringer Ingelheim's nintedanib currently in late stage development.  .

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    It's a method that is also seeing Boehringer enter the increasingly attractive rare diseases market through its investigational drug nintedanib, which is in studies assessing its effectiveness as a treatment ... This is in addition to nintedanib's

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics